Amorfix Life Science (ARFXF) 0.3120 $ARFXF
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
M2 - Tue Apr 22, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8ckvd2/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering. One of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity. Key vendors dominating this space include - Covis Pharmaceutical Inc. - Eisai Co. Ltd. - GlaxoSmithKline plc - Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are - Amorfix Life Sciences Ltd. - BrainStrom Cell Therapeutics Inc. - Newron Pharmaceuticals S.p.A - Neuraltus Pharmaceuticals Inc. - Nutra Pharma Corp. - Oxford BioMedica plc - Pharnext SAS - Q-Therapeutics Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Late Stage Pipeline Snapshot - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/8ckvd2/global
Research Reports: Kidney Cancer - Pipeline Review, H2 2013
M2 - Wed Nov 27, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/jnwbgg/kidney_cancer) has announced the addition of the "Kidney Cancer - Pipeline Review, H2 2013" report to their offering. 'Kidney Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. Scope - A snapshot of the global therapeutic scenario for Kidney Cancer. - A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Kidney Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Amorfix Life Sciences Ltd. Astellas Pharma Inc. Onyx Pharmaceuticals, Inc. Patrys Limited Dendreon Corporation Green Cross Corporation Rexahn Pharmaceuticals, Inc. Antisense Pharma GmbH Chipscreen Biosciences Ltd CIMAB S.A. Aurigene Discovery Technologies Limited Alethia Biotherapeutics Inc. GenSpera, Inc. Cerulean Pharma, Inc. Gene Signal International SA. Neotropix, Inc. Deciphera Pharmaceuticals, LLC MSM Protein Technologies, Inc. Vascular Biogenics Ltd. Pharminox Limited Esperance Pharmaceuticals, Inc. Welichem Biotech Inc. Cellceutix Corporation TRACON Pharmaceuticals, Inc. Advanced Cancer Therapeutics RECEPTA Biopharma S.A. Mediolanum farmaceutici S.p.A. FCB-Pharmicell Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/jn...ney_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Melanoma Report - Pipeline Review
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tjxbsj/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2013" report to their offering. 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Melanoma. Scope - A snapshot of the global therapeutic scenario for Melanoma. - A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Melanoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. 30 of the Companies Involved in Melanoma Therapeutics Development - Johnson & Johnson - Vical Incorporated - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Viralytics Ltd. - GlaxoSmithKline plc - Nektar Therapeutics - Antigenics, Inc. - Inovio Biomedical Corporation - medac GmbH - Merck & Co., Inc. - Lentigen Corporation - Generex Biotechnology Corporation - Plexxikon Inc. - Amorfix Life Sciences Ltd. - Prolexys Pharmaceuticals, Inc. - Aposense Ltd. - Histogen, Inc. - Novartis AG - Aphios Corporation - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - SuperGen, Inc. - Teva Pharmaceutical Industries Limited - Alfacell Corporation - Bayer AG - MannKind Corporation For more information visit http://www.researchandmarkets.com/research/tjxbsj/melanoma
IIROC Trade Resumption - Amorfix Life Sciences Ltd.
Newsfile Corp - Wed Jun 05, 8:35AM CDT
Trading resumes in:
IIROC Trade Halt - Amorfix Life Sciences Ltd.
Newsfile Corp - Wed Jun 05, 8:00AM CDT
The following issues have been halted by IIROC:
Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013 Reviews Key Players Involved In the Therapeutic Development for Amyotrophic Lateral Sclerosis
M2 - Fri Apr 12, 11:28AM CDT
Research and Markets has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Amyotrophic
Amorfix announces progress on ALS program
CNW Group - Wed Mar 20, 6:00AM CDT
TSX: AMF
Amorfix announces third quarter fiscal 2013 results and financing
CNW Group - Thu Feb 14, 6:30AM CST
TSX: AMF
Pharmaceutical Executive Warren Whitehead Joins Amorfix as Chief Financial Officer
CNW Group - Thu Jan 31, 6:00AM CST
TSX: AMF
Amorfix and QPS to collaborate on Alzheimer's disease project
CNW Group - Tue Jan 29, 6:00AM CST
TSX: AMF
Amorfix to present cancer therapeutic program at AACR 2013
CNW Group - Thu Jan 24, 6:00AM CST
TSX: AMF
Amorfix provides update on ALS diagnostic program
CNW Group - Tue Jan 22, 6:00AM CST
TSX: AMF
Blood Cancer - Pipeline Review, H2 2012 Report Features Players such as Boehringer Ingelheim GmbH and Amgen Inc.
M2 - Thu Jan 17, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j8jnc/blood_cancer) has announced the addition of Global Markets Direct's new report "Blood Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Blood Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Cancer. Blood Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Blood Ca
Amorfix to present corporate overview at the Biotech Showcase 2013 conference
CNW Group - Fri Jan 04, 6:00AM CST
TSX: AMF
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
M2 - Tue Apr 22, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8ckvd2/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering. One of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity. Key vendors dominating this space include - Covis Pharmaceutical Inc. - Eisai Co. Ltd. - GlaxoSmithKline plc - Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are - Amorfix Life Sciences Ltd. - BrainStrom Cell Therapeutics Inc. - Newron Pharmaceuticals S.p.A - Neuraltus Pharmaceuticals Inc. - Nutra Pharma Corp. - Oxford BioMedica plc - Pharnext SAS - Q-Therapeutics Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Late Stage Pipeline Snapshot - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/8ckvd2/global
Research Reports: Kidney Cancer - Pipeline Review, H2 2013
M2 - Wed Nov 27, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/jnwbgg/kidney_cancer) has announced the addition of the "Kidney Cancer - Pipeline Review, H2 2013" report to their offering. 'Kidney Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. Scope - A snapshot of the global therapeutic scenario for Kidney Cancer. - A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Kidney Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Amorfix Life Sciences Ltd. Astellas Pharma Inc. Onyx Pharmaceuticals, Inc. Patrys Limited Dendreon Corporation Green Cross Corporation Rexahn Pharmaceuticals, Inc. Antisense Pharma GmbH Chipscreen Biosciences Ltd CIMAB S.A. Aurigene Discovery Technologies Limited Alethia Biotherapeutics Inc. GenSpera, Inc. Cerulean Pharma, Inc. Gene Signal International SA. Neotropix, Inc. Deciphera Pharmaceuticals, LLC MSM Protein Technologies, Inc. Vascular Biogenics Ltd. Pharminox Limited Esperance Pharmaceuticals, Inc. Welichem Biotech Inc. Cellceutix Corporation TRACON Pharmaceuticals, Inc. Advanced Cancer Therapeutics RECEPTA Biopharma S.A. Mediolanum farmaceutici S.p.A. FCB-Pharmicell Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/jn...ney_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Melanoma Report - Pipeline Review
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tjxbsj/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2013" report to their offering. 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Melanoma. Scope - A snapshot of the global therapeutic scenario for Melanoma. - A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Melanoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. 30 of the Companies Involved in Melanoma Therapeutics Development - Johnson & Johnson - Vical Incorporated - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Viralytics Ltd. - GlaxoSmithKline plc - Nektar Therapeutics - Antigenics, Inc. - Inovio Biomedical Corporation - medac GmbH - Merck & Co., Inc. - Lentigen Corporation - Generex Biotechnology Corporation - Plexxikon Inc. - Amorfix Life Sciences Ltd. - Prolexys Pharmaceuticals, Inc. - Aposense Ltd. - Histogen, Inc. - Novartis AG - Aphios Corporation - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - SuperGen, Inc. - Teva Pharmaceutical Industries Limited - Alfacell Corporation - Bayer AG - MannKind Corporation For more information visit http://www.researchandmarkets.com/research/tjxbsj/melanoma
IIROC Trade Resumption - Amorfix Life Sciences Ltd.
Newsfile Corp - Wed Jun 05, 8:35AM CDT
Trading resumes in:
IIROC Trade Halt - Amorfix Life Sciences Ltd.
Newsfile Corp - Wed Jun 05, 8:00AM CDT
The following issues have been halted by IIROC:
Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013 Reviews Key Players Involved In the Therapeutic Development for Amyotrophic Lateral Sclerosis
M2 - Fri Apr 12, 11:28AM CDT
Research and Markets has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Amyotrophic
Amorfix announces progress on ALS program
CNW Group - Wed Mar 20, 6:00AM CDT
TSX: AMF
Amorfix announces third quarter fiscal 2013 results and financing
CNW Group - Thu Feb 14, 6:30AM CST
TSX: AMF
Pharmaceutical Executive Warren Whitehead Joins Amorfix as Chief Financial Officer
CNW Group - Thu Jan 31, 6:00AM CST
TSX: AMF
Amorfix and QPS to collaborate on Alzheimer's disease project
CNW Group - Tue Jan 29, 6:00AM CST
TSX: AMF
Amorfix to present cancer therapeutic program at AACR 2013
CNW Group - Thu Jan 24, 6:00AM CST
TSX: AMF
Amorfix provides update on ALS diagnostic program
CNW Group - Tue Jan 22, 6:00AM CST
TSX: AMF
Blood Cancer - Pipeline Review, H2 2012 Report Features Players such as Boehringer Ingelheim GmbH and Amgen Inc.
M2 - Thu Jan 17, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j8jnc/blood_cancer) has announced the addition of Global Markets Direct's new report "Blood Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Blood Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Cancer. Blood Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Blood Ca
Amorfix to present corporate overview at the Biotech Showcase 2013 conference
CNW Group - Fri Jan 04, 6:00AM CST
TSX: AMF
